Skip to content

Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions

Added Value of Preoperative Contrast Enhanced Mammography (PROCEM) in Staging of Malignant Breast Lesions - a Prospective Randomized Multicenter Trial

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04437602
Acronym
PROCEM
Enrollment
441
Registered
2020-06-18
Start date
2020-11-02
Completion date
2029-12-31
Last updated
2024-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Contrast Enhanced Mammography, Preoperative staging

Brief summary

Patients diagnosed with breast cancer after routine assessment with digital mammography and ultrasound and scheduled for primary surgery are included in the trial. The patients are randomized 1:1 to go through additional contrast enhanced mammography (CEM) or no further imaging preoperatively. Primary endpoint is rate of patients with change of treatment: a) mastectomy instead of partial mastectomy due larger unifocal or multifocal extent, b) partial mastectomy instead of mastectomy due to improved demarcation of the tumour area, c) bilateral surgery instead of unilateral due to findings of contralateral cancer, d) neoadjuvant therapy instead of primary surgery due to more advanced disease. Rate of reoperation and rate of avoidable mastectomies are secondary endpoints.

Interventions

DIAGNOSTIC_TESTContrast Enhanced Mammography (CEM)

Additional CEM in preoperative staging

Sponsors

Region Halland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Prospective Randomized Trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Planned primary surgery for suspicious or verified breast malignancy Age of 18 years and above Signed informed consent

Exclusion criteria

* Planned neoadjuvant therapy On-going pregnancy Iodinated contrast agent allergy Renal failure (abnormal S-creatinine) Untreated thyreotoxicosis Severe heart failure Myastenia gravis Breast implant Local recurrence as index lesion Inability to understand and comprehend oral and written information of the study

Design outcomes

Primary

MeasureTime frameDescription
Rate of patients with change of primary treatment due to findings at additional CEMWithin two months after diagnosis of breast cancerMastectomy instead of partial mastectomy due to findings of multifocal disease, mastectomy instead of partial mastectomy due to larger unifocal extent, partial mastectomy instead of mastectomy due to improved demarcation of tumour area, bilateral surgery due to findings of contralateral cancer, primary neoadjuvant treatment instead of primary surgery due to more advanced disease

Secondary

MeasureTime frameDescription
Rate of reoperationsWithin three months after diagnosis of breast cancerNumber of reoperations due to inadequate margins
Rate of avoidable mastectomiesWithin three months after diagnosis of breast cancerPatients operated with mastectomy where histopathology shows extent less than 3 cm

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026